Iguratimod as an alternative therapy for systemic sclerosis and prevention of the occurrence of ischemic digital ulcer
ObjectivesThis study aimed to assess the effectiveness of iguratimod (IGU) as an alternative treatment for systemic sclerosis (SSc), especially in the prevention of ischemic digital ulcers (DUs).MethodsWe constructed two cohorts from the Renji SSc registry. In the first cohort, SSc patients receivin...
Main Authors: | Qingran Yan, Bei Liu, Jieying Wang, Hanlin Yin, Qianqian Li, Liangjing Lu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-05-01
|
Series: | Frontiers in Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2023.1113408/full |
Similar Items
-
Iguratimod attenuated fibrosis in systemic sclerosis via targeting early growth response 1 expression
by: Lichong Shen, et al.
Published: (2023-08-01) -
Iguratimod: Novel Molecular Insights and a New csDMARD for Rheumatoid Arthritis, from Japan to the World
by: Yuji Nozaki
Published: (2021-05-01) -
Iguratimod efficacy in palindromic rheumatism treatment
by: Fangfang Yuan, et al.
Published: (2023-06-01) -
Iguratimod Ameliorates the Severity of Secondary Progressive Multiple Sclerosis in Model Mice by Directly Inhibiting IL-6 Production and Th17 Cell Migration via Mitigation of Glial Inflammation
by: Satoshi Nagata, et al.
Published: (2023-09-01) -
Iguratimod, an allosteric inhibitor of macrophage migration inhibitory factor (MIF), prevents mortality and oxidative stress in a murine model of acetaminophen overdose
by: Joshua Bloom, et al.
Published: (2024-03-01)